Bank of America
LVTX

Bank of America’s LAVA Therapeutics LVTX Stock Holding History

Bank of America’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-400
Closed -$720 – 8312
2024
Q2 		$720 Sell
400
-15,011
-97% -$39.6K ﹤0.01% 7286
2024
Q1 		$51.3K Buy
+15,411
New +$33.9K ﹤0.01% 6508
2023
Q2 		– Sell
-32,240
Closed -$53.5K – 7841
2023
Q1 		$53.5K Buy
32,240
+32,084
+20,567% +$89.8K ﹤0.01% 6486
2022
Q4 		$546 Buy
+156
New +$716 ﹤0.01% 7417
2022
Q1 		– Sell
-1
Closed – – 8544
2021
Q4 		$0 Sell
1
-9,069
-100% -$59.5K ﹤0.01% 8457
2021
Q3 		$54K Buy
+9,070
New +$65.3K ﹤0.01% 7010

Other funds holding LVTX

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PFA
Pathway Financial Advisors South Burlington, Vermont $857M AUM 17.21% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America's LVTX Position: Q3 2024 in Review

Bank of America sold out of LAVA Therapeutics (LVTX) in Q3 2024, closing a stake of 400 shares — an estimated $720 sold.

Bank of America first reported a position in LVTX in Q3 2021 and held it in 6 quarters. The position peaked at $54K in Q3 2021. 21 funds tracked by Wall St. Rank hold LVTX as of Q3 2024.

  • Bank of America reported no remaining LAVA Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Bank of America sold 400 LAVA Therapeutics shares in Q3 2024, an estimated $720.
  • Bank of America first reported a position in LAVA Therapeutics in Q3 2021 and held it in 6 quarters.
  • Bank of America's LAVA Therapeutics position peaked at $54K in Q3 2021.
  • 21 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q3 2024.

Based on Bank of America's 13F filing for Q3 2024, filed 14 Nov 2024.